Key facts
- Blue Armor’s last known valuation is $1.9M (Dec 2025).
- It has raised $950K; the latest was Angel (individual) ($740K) in Dec 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Blue Armor
- ·The full record, as it builds
Funding rounds
No funding rounds for Blue Armor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Blue Armor
Developer of the first Messenger RNA vaccine platform designed to provide rapid, flexible, and safe protection against major salmon pathogens. The company platform for aquaculture, featuring rapid adaptation to new strains, strong immune response with lower doses, and a non-genetically modified, adjuvant-free safety profile, enables faster, safer protection against major salmon pathogens and lice, enabling fish farmers worldwide to respond swiftly to disease threats and support sustainable operations.
- Sector
- Healthcare
- HQ
- Wallonia, Belgium
- Founded
- 2025
- Website
- b-armor.com/
- Ownership
- Privately Held (backing)
Blue Armor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Blue Armor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Blue Armor in its N-PORT filings yet. We sweep new filings monthly.